Therefore, the European Society of Oncology (ESMO) recommends HER2 testing for metastatic GC, and the American Society of Clinical Oncology (ASCO) recommends HER2 testing for all primary or metastatic GC lesions in patients who can tolerate combination therapy (127). Here, ERBB2 is linked to gastric cancer.